$IMNN

Eylward Susan sold $4K of IMNN

Eylward Susan (General Counsel and Corp Sec) sold 2,449 shares of Imunon, Inc. (IMNN) at $1.63 on 2026-08-17.

Original reporting
SEC EDGAR · Eylward Susan
Published Aug 17, 2026, 8:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 9:27 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IMNN
Neutral
medium confidence
Mentioned
$IMNN
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IMNNNeutralLow
01

Why it matters

The newest fact is the specific open-market sale by the company’s General Counsel and Corp Sec on 2026-08-17, including price and post-transaction holdings.

02

Market read

Traders may note insider selling as a sentiment datapoint, but there is no accompanying operational or financial update in the text.

03

What to watch

The filing does not disclose reasons for the sale, whether it was part of broader compensation/vesting activity, or any concurrent corporate developments.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-17, after-hours disclosure

Background

The article is an SEC Form 4 insider transaction for Imunon, Inc. (IMNN).

Company-level read

Ticker impact

$IMNNNeutralMedium confidence
Context

Imunon insider Eylward Susan, General Counsel and Corp Sec, sold 2,449 shares at $1.6303 on 2026-08-17 via an open-market sale.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than a new company catalyst.

Evidence & confidence

Form 4 provides transaction details (size, price, post-sale holdings) but no accompanying corporate event, guidance, or operational update.

Market effects

No clear sector read-through from a single insider sale at a small value.

None.

None.

Counterpoint

Insider sales can be planned for liquidity or tax needs; the absence of a stated 10b5-1 plan does not automatically imply negative information.

Key entities

  • Imunon, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Eylward Susan

    General Counsel and Corp Sec who sold 2,449 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IMNNMedAI 8/10

Imunon (IMNN) Q2 2026 Earnings Call Transcript

Imunon (IMNN) held its Q2 2026 earnings call. Management reported Phase 2 OVATION II median overall survival of 45.1 months vs 30.4 months, and PARP maintenance survival of 65.6 vs 41.4 months. Q2 R&D was $1.5M, G&A $1.3M, net loss $2.8M. Cash was $6.9M after a $10M financing.

$IMNNMed

Imunon, Inc. (IMNN): Results of Operations and Financial Condition

Imunon, Inc. (IMNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enroll

$IMNNMed

EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study - Im

Imunon Inc. (NASDAQ:IMNN) updated its pivotal Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer. The company said site activation and enrollment are ahead of forecasts, with full enrollment expected by Q2 2029. It reported no cytokine release syndrome or serious immune-related adverse events and noted two interim analyses that could support an early BLA. Shares rose 1.95% to $1.57 premarket.

$IMNNMed

Imunon, Inc.: IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer

IMUNON (Nasdaq: IMNN) provided an update on its pivotal Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer. The company said enrollment is ahead of plan, with a study rate of about 0.5 patients per site per month versus 0.3 planned, and it now expects completion in Q2 2029. It reported no cytokine release syndrome and comparable safety versus control.